Our study demonstrated that dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling, was highly effective in improving the clinical outcomes of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This evidence concerns the gene IL13 and Nasal polyposis.